Form 4: Larimar Therapeutics Director Acquires Stock Options

Jeffrey W. Sherman, a director at Larimar Therapeutics, acquired 19,000 stock options on May 13, 2025, exercisable at $1.875.

Summary

• On May 13, 2025, Jeffrey W. Sherman, a director of Larimar Therapeutics, Inc., acquired 19,000 stock options.
• The options have an exercise price of $1.875.
• The options vest on the earlier of May 13, 2026, or the date of the company's next annual meeting of stockholders, contingent upon continued service on the Board of Directors.
• The options expire on May 13, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally viewed as a positive sign, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continued service on the board, suggesting an expectation of ongoing involvement.

Industry Context

This is a standard Form 4 filing, reflecting a transaction by a company insider. Such filings are common and provide transparency into insider activity.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, director, Larimar Therapeutics, LRMR, Form 4, beneficial ownership, Sherman, Jeffrey W. Sherman